Assessment and Tracking of Long-Term Alefacept (LFA-3/IgG1 Fusion Protein) Pregnancy Exposure Registry

Trial Profile

Assessment and Tracking of Long-Term Alefacept (LFA-3/IgG1 Fusion Protein) Pregnancy Exposure Registry

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 10 Dec 2013

At a glance

  • Drugs Alefacept (Primary)
  • Indications Psoriasis
  • Focus Adverse reactions
  • Sponsors Astellas Pharma US
  • Most Recent Events

    • 09 Mar 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
    • 09 Mar 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
    • 09 Mar 2012 Actual patient number is 3 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top